Moores Members Ranked Among 2023 Highly Cited Researchers |
According to Clarivate’s 2023 Highly Cited Researchers list, UC San Diego not only ranks 7th highest among universities worldwide, but also boasts the highest number of influential researchers in the UC system, many of whom are Moores Members.
|
|
|
Napoleone Ferrara, MD Awarded the Prince Mahidol Award |
Dr. Napoleone Ferrara has been awarded the 2023 Prince Mahidol Award in the Field of Medicine, by the Prince Mahidol Award Foundation, which was established by the royal permission of His Majesty the King Bhumibol Adulyadej of Thailand. Prior awardees of this award include Dr. Douglas R. Lowy, NCI Acting Director.
|
Rana McKay, MD Awarded 2023 Barry Hoeven Memorial Kidney Cancer Research Project Grant and 2023 Kidney Cancer Association (KCA) Grant |
Dr. Rana McKay and University Hospitals Seidman Cancer Center researcher Dr. Peter Barata have been awarded the 2023 Barry Hoeven Memorial Kidney Cancer Research Project Grant. This $250,000 award supports their study, Dissecting the Predictive and Prognostic Impact of RNA Signatures in Advanced Renal Cell Carcinoma (RCC).
Moreover, Dr. McKay was awarded one of six grants given by the KCA. She received one of two KCA Trailblazer Awards, which fund exceptional research in any aspect of kidney cancer, for her research to predict response to immunotherapy among RCC patients.
|
NCI Research Funding Opportunities |
In addition to the select NCI research funding opportunities that appear each week in the Featured Funding Opportunities section of the newsletter below, Moores Members can peruse a complete set of categorized NCI funding opportunities available by simply clicking this blue button:
|
|
|
Wednesday, December 20 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
Monday, January 8, 2024 | 3:00 p.m. to 4:00 p.m.
Sanford Consortium for Regenerative Medicine, Room 1013 A/B
|
Wednesday, January 10, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
Wednesday, January 10, 2024 | 12:00 p.m. to 1:00 p.m.
Leichtag Biomedical Research Building, Room 107
|
|
|
FEATURED FUNDING OPPORTUNITIES |
NCI P50 SPORE grants support state-of-the-art investigator-initiated translational research that contribute to improved prevention, early detection, diagnosis, and treatment of either an organ-specific cancer or a highly related group of cancers.
Deadline: January 25, 2024; May 25, 2024; September 25, 2024
|
This mechanism promotes the discovery, development, and validation of real-world digital endpoints derived from data generated by existing remote or wearable devices. These endpoints will be used for monitoring not only the experience of pain, but also its progression, response to interventions, and impact on quality of life.
Deadline: January 30, 2023
|
The goal of this program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs. As such, this notice of funding opportunity (NOFO) will support creative educational activities that target courses for skills development.
Coming Deadline: January 25, 2024 (Standard NIH Due Dates Apply for Subsequent Proposals)
|
The goal of this program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs. As such, this NOFO will support creative educational activities that target research experiences.
Coming Deadline: January 25, 2024 (Standard NIH Due Dates Apply for Subsequent Proposals)
|
|
|
| A comparative atlas of single-cell chromatin accessibility in the human brain |
Bing Ren, PhD (Structual and Functional Genomics)
|
|
|
|
|
RANK ligand converts the NCoR/HDAC3 co-repressor to a PGC1β- and RNA-dependent co-activator of osteoclast gene expression |
Gene W. Yeo, PhD (Structural and Functional Genomics) and James T. Kadonaga, PhD (Cancer Biology Signaling)
|
|
|
|
| Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019
|
Xinlian Zhang, PhD (Cancer Biology and Signaling), Rohit Loomba, MD (Cancer Control Program), and Bernd Schnabl, MD (Cancer Biology Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
D926XC00001: A Phase III Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) with or without Durvalumab Versus Investigators Choice of Therapy in Patients with Stage IIII Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPIONBreast03) | PI: Rebecca Shatsky, MD
NCT: NCT05629585
|
PRO1184-001: Phase I/II Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors |
PI: Sandip Patel, MD
NCT: NCT05579366
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
C-Change Mentoring and Leadership Institute for Mid-Career Faculty |
This 1-year fellowship program is geared to the needs of all mid-career faculty in academic medicine across all categories of race and gender. Up to 18 faculty will begin the program in October 2024. Physicians and scientists from all departments in academic health centers are welcome to apply.
Learn More
|
|
|
|
